LION Bioscience Sells Bioinformatics Business
News Apr 05, 2006
LION bioscience AG has successfully completed the sale of its bioinformatics business to BioWisdom Ltd, UK. The consideration will be up to EUR 4 million and the deal is due to be completed by April 4, 2006.
As a result of this transaction, the company has achieved a major milestone in its restructuring plans, which commenced over a year ago. "We have achieved a satisfactory result through this disposal. All obligations resulting from the bioinformatics business have been assigned to the buyer, therefore, we can now focus on the future business, based on a clean and strengthened position," said Peter Willinger, CFO of LION bioscience.
The bioinformatics unit, comprising the 100%-owned subsidiaries, LION Bioscience Ltd., Cambridge, UK and LBAV, Inc, Cambridge, MA, USA, will be taken over by BioWisdom Ltd., a company specializing in providing healthcare intelligence to business leaders in the pharmaceutical and biotechnical industry. The sales price consists of a fixed and variable payment. The latter is based on the business development over the next 12 months.
In connection with the sale of the bioinformatics business, the planned reduction of the Management Board, approved by the shareholders’ meeting in March 2005, has taken place, with Dr. Thure Etzold resigning as CEO as of April 4, 2006. Peter Willinger will be the sole member of the Management Board.
"The disposal of the bioinformatics business was a primary precondition for the future strategy of LION and its position in the market," said Peter Willinger. "LION is currently reviewing potential promising options within the life science business. We are confident, that we will be able to provide more specific updates with this regards to our position shortly," added Willinger.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019